SEC Tracker
Get the app
BDSX · XBRL financial data

Biodesix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BDSX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue13,49114,668*14,81817,92518,15120,429*17,95820,01821,76828,755*25,55526,861
Research and development1,9381,889*2,0402,5582,5472,414*2,8703,2692,9922,870*3,2853,135
Selling, general and administrative15,49616,251*20,55619,66020,01620,219*20,44822,41121,71422,972*24,26124,282
Total operating expenses20,66321,538*25,83926,16226,74227,078*27,09429,73728,81930,722*31,75632,249
Operating income (loss)(7,172)(6,870)*(11,021)(8,237)(8,591)(6,649)*(9,136)(9,719)(7,051)(1,967)*(6,201)(5,388)
Interest expense2,3862,329*2,5291,9362,0411,752*1,6851,8982,0742,059*1,9771,982
Other income (expense)(3,777)(2,269)*(64)(387)374—9851409—38597
Income tax expense (benefit)0*0*00*0*0*00*0*0*00*
Net income (loss)(10,949)(9,139)*(13,614)(10,808)(10,258)(8,251)*(11,101)(11,468)(8,716)(3,980)*(7,793)(7,273)
Earnings per share, basic‡ USD per share(2.80)(2.00)*(2.80)(1.60)(1.40)(1.20)*(1.60)(1.60)(1.16)(0.50)*(0.81)(0.71)
Earnings per share, diluted‡ USD per share(2.80)(2.00)*(2.80)(1.60)(1.40)(1.20)*(1.60)(1.60)(1.16)(0.50)*(0.81)(0.71)
Weighted average shares, basic‡ thousands of shares3,9854,617*4,8586,3587,3157,383*7,3277,3337,5008,037*9,65610,296
Weighted average shares, diluted‡ thousands of shares3,9854,617*4,8586,3587,3157,383*7,3277,3337,5008,037*9,65610,296
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (BDSX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents19,84126,28411,49142,21931,40626,24517,60320,72816,60418,98725,57229,996
Accounts receivable5,7777,6799,89310,1288,0368,6037,6397,45112,6749,0369,5009,113
Total current assets28,88639,68328,47957,57944,01739,48429,62232,44533,40132,51840,91243,565
Property and equipment, net25,39527,86728,57528,01928,68327,82826,96626,13525,46224,81724,19223,803
Right-of-use asset2,0931,7451,5571,7671,9181,7671,9622,1062,9422,9973,1883,542
Goodwill15,03115,03115,03115,03115,03115,03115,03115,03115,03115,03115,03115,031
Total assets86,78699,09687,201115,841102,74397,24486,24187,74088,72287,47694,63795,326
Accounts payable2,9042,9293,2132,2202,5372,1942,9252,9733,6173,0803,6512,160
Accrued liabilities6,9467,7107,8988,3248,55310,0647,4039,6849,72011,0338,23410,411
Total current liabilities32,64933,41631,23017,55212,96314,31713,31615,16018,15217,43614,48915,291
Lease liability, non-current24,63625,16325,34725,47825,19124,82824,48024,11124,41224,03923,66923,370
Total liabilities88,23294,51692,70379,58174,88676,36875,18186,60290,44489,94185,50586,182
Accumulated deficit(410,427)(419,566)(433,180)(443,988)(454,246)(462,497)(473,598)(485,066)(493,782)(497,762)(505,555)(512,828)
Total stockholders' equity(1,446)4,580(5,502)36,26027,85720,87611,0601,138(1,722)(2,465)9,1329,144
Total liabilities and equity86,78699,09687,201115,841102,74397,24486,24187,74088,72287,47694,63795,326
Common shares outstanding (cover page)‡ thousands of shares4,5244,8475,7347,2597,2737,2997,3287,3327,9569,85810,10910,551
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (BDSX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,949)(9,139)*(13,614)(10,808)(10,258)(8,251)*(11,101)(11,468)(8,716)(3,980)*(7,793)(7,273)
Stock-based compensation954*1,081*2,6401,218*1,515*1,265*9721,039*1,053*1,075*1,115820*
Net cash from operating activities(3,838)*(12,283)*(15,311)(18,571)*(10,671)*(4,096)*(8,602)(6,568)*(8,879)*778*(10,168)(1,562)*
Purchases of property and equipment5,842*2,984*2341,926*231*839*7451*48*86*81197*
Net cash from investing activities(5,883)*(3,001)*(273)(1,997)*(286)*(884)*(137)(95)*(67)*(104)*(144)(254)*
Proceeds from issuing common stock—12,810*62555,000*0*0*———2,320*17,2146,672*
Repayments of long-term debt12*13*1312*13*13*75*4*5*51*
Net cash from financing activities12,152*21,728*79151,296*144*(181)*979,789*4,822*1,709*16,8976,240*
Net change in cash2,431*6,444*(14,793)30,728*(10,813)*(5,161)*(8,642)3,126*(4,124)*2,383*6,5854,424*

Compare with peers

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Biodesix29,99626,861(1,562)*10.6M19.2 quarters 10-QJun 30, 2026
American Shared Hospital Services6,5118,4302,236*6.7M— 10-QJun 30, 2026
CapForce14450,000(618)*12.4M0.2 quarters 10-QJun 30, 2026
Ludwig Enterprises18not reported(153)167.2M1.3 quarters 10-QMar 31, 2026
BioNexus Gene Lab1,23376(422)*2.9M2.9 quarters 10-QJun 30, 2026
BillionToOne548,628109,4489,136*not reported— 10-QJun 30, 2026
Sera Prognostics4,39830(6,311)*not reported7.4 quarters 10-QJun 30, 2026
Aclarion16,28525(2,657)*2.9M6.1 quarters 10-QJun 30, 2026
Freenome437not reported(130)*not reported3.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.